IDH1 and central nervous system cancer: In recent years, with the deepening of research on the basic and clinical characteristics of glioma, the field of glioma has also been further developed; more and more biomarkers and potential treatment targets for glioma were proven to play important roles in disease progression, such as isocitrate dehydrogenase I (IDH) mutation, 1p/19q co-deletion, TP53 mutation, telomerase reverse transcriptase (TERT) promoter mutation, h3k27m mutation, and other key molecules; these molecular information are gradually used as pathological diagnosis [4].